Clear Harbor Asset Management LLC Decreases Position in Illumina, Inc. (NASDAQ:ILMN)

Clear Harbor Asset Management LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 17.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 14,092 shares of the life sciences company’s stock after selling 2,950 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Illumina were worth $1,962,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in ILMN. Vanguard Group Inc. increased its position in shares of Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after acquiring an additional 2,336,935 shares during the period. Polen Capital Management LLC increased its position in shares of Illumina by 0.6% in the third quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company’s stock valued at $703,782,000 after acquiring an additional 29,153 shares during the period. Loomis Sayles & Co. L P increased its position in shares of Illumina by 5.5% in the third quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock valued at $550,212,000 after acquiring an additional 208,267 shares during the period. Bank of New York Mellon Corp increased its position in shares of Illumina by 6.6% in the third quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after acquiring an additional 225,074 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Illumina by 1.9% in the first quarter. Geode Capital Management LLC now owns 2,928,326 shares of the life sciences company’s stock valued at $679,269,000 after acquiring an additional 54,951 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 1.0 %

Shares of NASDAQ ILMN traded down $1.36 during midday trading on Thursday, hitting $137.32. The stock had a trading volume of 916,873 shares, compared to its average volume of 1,786,282. The business’s 50 day moving average is $138.39 and its 200-day moving average is $129.38. The company has a market cap of $21.82 billion, a P/E ratio of -18.71 and a beta of 1.19. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $233.42. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The business’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.14 earnings per share. As a group, analysts predict that Illumina, Inc. will post 0.91 EPS for the current year.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen acquired 7,330 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $258.00 price objective on shares of Illumina in a research report on Friday, February 9th. Wolfe Research began coverage on shares of Illumina in a research note on Wednesday, December 13th. They set an “outperform” rating and a $175.00 target price on the stock. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Finally, Barclays lifted their target price on shares of Illumina from $50.00 to $80.00 and gave the company an “underweight” rating in a research note on Thursday, January 25th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $166.95.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.